Product Performance

Strong Accuracy and Outcomes Across All Major Indicators

A demonstrated 8.5% Mean Absolute Relative Difference (MARD)¹
Fluorescence-based technology unaffected by ascorbic acid and acetaminophen²
Excellent accuracy in the 2.2-3.3 mmol/L hypoglycemic range (86.5% within 15/15 YSI)³
Sensor adherence of 23+ hours per day^4,5
A clinically meaningful HbA1c reduction across major studies^3-5

For more information on Eversense’s safety and performance, contact us to get a copy of our Outcomes Summary.

1 Christiansen MP. PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. 2 Sensor Chemical Interference Screen Summary Report. Senseonics internal reporting, USA, July 2015. 3 Eversense FDA Summary of Safety and Effectiveness Data (SSED) 4 Data on file. Senseonics 2019. 5 PRECISE Supplement. Data on file. Senseonics 2018. 6 Lind M, Diabetes Metab Syndr. 2008;2(4) 282-293. 7 Kropff, J. PRECISE study. Diabetes Care, 40(1), 63-68.

MKT-001296 Rev1

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.